Data Repository of Antimicrobial Peptides (DRAMP, http://dramp.cpu-bioinfor.org/) is an open-access comprehensive database containing general, patent and clinical antimicrobial peptides (AMPs). Currently DRAMP has been updated to version 2.0, it contains a total of 19,899 entries (newly added 2,550 entries), including 5,084 general entries, 14,739 patent entries, and 76 clinical entries. The update covers new entries, structures, annotations, classifications and downloads. Compared with APD and CAMP, DRAMP contains 14,040 (70.56% in DRAMP) non-overlapping sequences. In order to facilitate users to trace original references, PubMed_ID of references have been contained in activity information. The data of DRAMP can be downloaded by dataset and activity, and the website source code is also available on dedicatedly designed download webpage. Although thousands of AMPs have been reported, only a few parts have entered clinical stage. In the paper, we described several AMPs in clinical trials, including their properties, indications and clinicaltrials.gov identifiers. Finally, we provide the applications of DRAMP in the development of AMPs.

Stapled antimicrobial peptides are an emerging class of artificial cyclic peptide molecules which have antimicrobial activity and potent structure stability. We previously published the Data Repository of Antimicrobial Peptides (DRAMP) as a manually annotated and open-access database of antimicrobial peptides (AMPs). In the update of version 3.0, special emphasis was placed on the new development of stapled AMPs, and a subclass of specific AMPs was added to store information on these special chemically modified AMPs. To help design low toxicity AMPs, we also added the cytotoxicity property of AMPs, as well as the expansion of newly discovered AMP data. At present, DRAMP has been expanded and contains 22259 entries (2360 newly added), consisting of 5891 general entries, 16110 patent entries, 77 clinical entries and 181 stapled AMPs. A total of 263 entries have predicted structures, and more than 300 general entries have links to experimentally determined structures in the Protein Data Bank. The update also covers new annotations, statistics, categories, functions and download links. DRAMP is available online at http://dramp.cpu-bioinfor.org/.

The growing problem of antibiotic-resistant microorganisms results in an urgent need for substitutes to conventional antibiotics with novel modes of action and effective activities. Antimicrobial peptides (AMPs), produced by a wide variety of living organisms acting as a defense mechanism against invading pathogenic microbes, are considered to be such promising alternatives. AMPs display a broad spectrum of antimicrobial activity and a low propensity for developing resistance. Therefore, a thorough understanding of AMPs is essential to exploit them as antimicrobial drugs. Considering this, we developed a comprehensive user-friendly data repository of antimicrobial peptides (DRAMP), which holds 17349 antimicrobial sequences, including 4571 general AMPs, 12704 patented sequences and 74 peptides in drug development. Entries in the database have detailed annotations, especially detailed antimicrobial activity data (shown as target organism with MIC value) and structure information. Annotations also include accession numbers crosslinking to Pubmed, Swiss-prot and Protein Data Bank (PDB). The website of the database comes with easy-to-operate browsing as well as searching with sorting and filtering functionalities. Several useful sequence analysis tools are provided, including similarity search, sequence alignment and conserved domain search (CD-Search). DRAMP should be a useful resource for the development of novel antimicrobial peptide drugs.

Antimicrobial peptides (AMPs) are potential candidates for treating multidrug-resistant bacterial infections, yet only a small number of them have progressed into clinical trials. The main challenges include the poor stability and hemolytic/cytotoxic properties of AMPs. Considering this, in the update of the Data Repository of Antimicrobial Peptides (DRAMP), a new annotation on serum and protease stability is added, and special efforts were made to update the hemolytic/cytotoxic information of AMPs. The DRAMP 4.0 currently holds 30 260 entries (8 001 newly added), consisting of 11 612 general entries, 17 886 patent entries, 96 clinical entries, 377 specific entries, 110 entries with stability data, and 179 expanded entries. A total of 2891 entries possess experimentally determined hemolytic activity information, while 2674 entries contain cytotoxicity data by experimental validation. The update also covers new annotations, statistics, categories, functions, and download links. DRAMP is available online at http://dramp.cpu-bioinfor.org/.

Cancer is a major cause of death worldwide despite significant advances in surgery and biology. Several recent studies have suggested that there is a close connection between tumorigenesis and inflammation. Cyclooxygenase-2 (COX-2), a link between inflammation and cancer, was proposed as a prime target for cancer therapy. However, the main available COX-2 inhibitors, nonsteroidal antiinflammatory drugs (NSAIDs), have several side effects that limit their application in cancer treatment. Additional research is needed to identify drugs that can regulate COX-2 or prostaglandin E2 (PGE2) with greater efficacy. Understanding the mechanism of COX-2/PGE2-mediated cancer and inflammation would be very useful for successful drug development. Progress of research and development into the role of COX related signaling both in inflammation and tumorigenesis in recent years has been summarized and introduced in this paper. Novel drugs designed to inhibit COX-2-related cancers are discussed to provide references for further development of novel drugs.